Background The first-in-class antibody-drug conjugate TAK-264 (formerly MLN0264) consists of an antibody targeting guanylyl cyclase C (GCC) conjugated to monomethyl auristatin E (MMAE) via a peptide linker. This phase II study evaluated the efficacy and safety of TAK-264 in patients with adenocarcin …

2013年5月20日 · Background: MLN0264, an investigational ADC that targets GCC, consists of a fully human monoclonal antibody conjugated to the cytotoxic microtubule disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. MMAE and the linker technology are licensed from Seattle Genetics.

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C Invest New Drugs . 2017 Oct;35(5):634-641. doi: 10.1007/s10637-017-0473-9.

2013年11月1日 · The transmembrane cell surface receptor GCC is expressed by ∼95% of primary and metastatic colorectal cancer (mCRC) tumors. MLN0264 has shown selective binding and antitumor activity in mouse xenograft models of mCRC expressing GCC, and is currently being investigated in a phase 1 study in patients with advanced gastrointestinal malignancies.

2017年2月11日 · The investigational ADC TAK-264 (formerly MLN0264), which we have evaluated in this study, consists of a human mAb that specifically targets guanylyl cyclase C (GCC) conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a peptide linker.

The investigational antibody-drug conjugate MLN0264 consists of a fully human monoclonal antibody targeting GCC linked to monomethyl auristatin E (MMAE) via a protease-cleavable linker. MMAE and the linker technology are licensed from Seattle Genetics. MLN0264 has shown antitumor activity in xenograft models of GCC-expressing tumors.

MLN0264 在表达鸟苷酸环化酶 C 的晚期胃肠道恶性肿瘤成年患者中进行的一项开放标签、剂量递增、第 1 阶段、首次人体研究. 这是一项开放标签、多中心、剂量递增、MLN0264 对表达鸟苷酸环化酶 C 的晚期胃肠道恶性肿瘤成人患者的首次人体研究。 本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。 研究人员寻找符合特定描述的人，称为资格标准。 这些标准的一些例子是一个人的一般健康状况或先前的治疗。 纳入标准： 排除标准： 请注意， …

2016年10月15日 · Purpose: To assess the safety, tolerability, and preliminary antitumor activity of the investigational anti-guanylyl cyclase C (GCC) antibody-drug conjugate TAK-264 (formerly MLN0264) in adult patients with advanced gastrointestinal malignancies.

2017年5月19日 · TAK-264 (formerly MLN0264) consists of a human monoclonal anti-GCC antibody conjugated to monomethyl auristatin E (MMAE) via a protease cleavable peptide linker .

2014年5月20日 · Background: This first-in-human study (NCT01577758) assessed the safety and tolerability, dose limiting toxicities (DLTs), maximum tolerated dose (MTD), pharmacokinetics, and preliminary antitumor activity of MLN0264 in adult patients (pts) with advanced gastrointestianl (GI) malignancies expressing the surface antigen guanylyl cyclase C (GCC ...